This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PSMA | |
|---|---|
| Name | Prostate-specific membrane antigen |
| Uniprot | NA |
PSMA
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in several human tissues and exploited as a biomarker and therapeutic target in oncology. Discovered through collaborative efforts spanning academic labs and biotechnology firms, PSMA has become central to advances in molecular imaging, targeted radionuclide therapy, and antibody engineering. Clinical and basic research on PSMA intersects with disciplines represented by institutions such as Johns Hopkins University, Memorial Sloan Kettering Cancer Center, and Mayo Clinic.
PSMA was initially identified by investigators working with monoclonal antibodies and prostate tissue specimens studied at centers like Stanford University and University of Michigan. Early characterization involved collaborations with groups at National Institutes of Health and biotech companies such as Amgen and Novartis. Interest in PSMA surged after clinical correlations published by teams at Dana-Farber Cancer Institute, Massachusetts General Hospital, and University of California, San Francisco linked PSMA expression to prostate pathology and therapeutic potential.
PSMA is a type II transmembrane protein with a short N-terminal cytoplasmic tail, a transmembrane domain, and a large extracellular domain that harbors enzymatic activity, characterized using techniques developed at Cold Spring Harbor Laboratory and Salk Institute. Structural biology efforts employing X-ray crystallography and cryo-electron microscopy from groups like Max Planck Institute and European Molecular Biology Laboratory resolved active-site architecture and zinc-binding motifs. Biochemical assays adapted from protocols at Rockefeller University demonstrated glutamate carboxypeptidase activity similar to enzymes studied at University of Cambridge and Karolinska Institutet. Post-translational modifications, including N-linked glycosylation mapped by researchers at Harvard Medical School and ETH Zurich, influence ligand binding and antibody recognition characterized in studies at Imperial College London.
Endogenous expression of PSMA was documented in tissues including prostate epithelium and non-prostatic sites such as the small intestine and kidney by investigators at University of Oxford and University of Toronto. Functional studies by groups at Columbia University and Yale University linked PSMA activity to folate metabolism and neurotransmitter processing analogous to enzymes studied at Uppsala University and Johns Hopkins University School of Medicine. Vascular expression in tumor-associated neovasculature was reported by teams at University of Pennsylvania and Vanderbilt University, informing angiogenesis research pursued at Weill Cornell Medicine and University College London.
Clinical correlations between PSMA expression and prostate carcinoma progression were established in cohorts assembled at Cleveland Clinic and Brigham and Women's Hospital. Multicenter studies involving MD Anderson Cancer Center and University of Chicago reported associations with tumor grade, metastasis, and castration-resistant disease, echoing findings from Memorial Sloan Kettering Cancer Center. PSMA upregulation in glioblastoma neovasculature and renal cell carcinoma was described by investigators at Johns Hopkins Hospital and The University of Texas Southwestern Medical Center. Reports from Karolinska University Hospital and Mayo Clinic Rochester documented PSMA expression in inflammatory and benign conditions, underscoring diagnostic nuance.
PSMA-targeted imaging agents such as small-molecule inhibitors and monoclonal antibodies were developed through collaborations among Advanced Accelerator Applications, Blue Earth Diagnostics, and academic groups at University of Basel and Technische Universität München. Clinical trials reported by European Organization for Research and Treatment of Cancer and National Cancer Institute demonstrated sensitivity and specificity in detecting metastatic prostate cancer using PET tracers derived from compounds optimized at University of Heidelberg and University of Freiburg. Imaging workflows integrating PSMA PET with modalities from vendors like Siemens Healthineers and GE Healthcare were validated in studies at Royal Marsden Hospital and Princess Margaret Cancer Centre.
Therapeutic strategies exploiting PSMA include antibody-drug conjugates, bispecific antibodies, and radioligand therapies developed by teams at Novartis (following acquisition of a biotech program) and researchers at Paul Scherrer Institute. Landmark clinical trials by consortia such as European Society for Medical Oncology and American Society of Clinical Oncology evaluated PSMA-targeted radiopharmaceuticals in castration-resistant cohorts enrolled at University of Bonn and University Hospital Zurich. Combination approaches pairing PSMA-directed agents with immune checkpoint inhibitors investigated in trials at Institut Gustave Roussy and Leiden University Medical Center reflect multidisciplinary efforts also seen at Fred Hutchinson Cancer Center.
Research reagents including monoclonal antibodies, recombinant PSMA constructs, and radiolabeled ligands were standardized through repositories and collaborations with Addgene, ATCC, and core facilities at European Molecular Biology Laboratory. Biomarker studies integrating PSMA imaging with genomic profiling from initiatives at The Broad Institute and Wellcome Sanger Institute have enabled correlative analyses linking PSMA signal to mutation patterns identified by consortia like The Cancer Genome Atlas and International Cancer Genome Consortium. Ongoing translational research at centers such as UCLA, Seoul National University, and Peking University continues to refine PSMA-based diagnostics and predictive models used in precision oncology.
Category:Proteins Category:Oncology